Opinion|Videos|October 24, 2024
Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection
Author(s)Toby Maher, MD, PhD
Key Takeaways
- IPF diagnosis relies on clinical evaluation, HRCT, and occasionally lung biopsy to identify usual interstitial pneumonia patterns.
- The average time to IPF diagnosis can be delayed up to two years due to symptom overlap with other conditions.
Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is diagnosed through specific imaging and tests, with an average diagnosis time that can delay effective treatment, emphasizing that early diagnosis is crucial for reducing disease severity and expanding available treatment options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How is IPF diagnosed, including specific tests and/or imaging, and what is the average time to diagnosis?
- What role does early diagnosis play in the severity of disease and the treatment options offered to patients with IPF?
Advertisement
Related to this article
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Advertisement
Advertisement
Trending on AJMC
1
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
5